Abstract The lack of methods to deliver transgene expression in spinal cord has hampered investigation of gene function and therapeutic targets for spinal cord diseases. Here, we report that a single intrathecal injection of recombinant adenoassociated virus rhesus-10 (rAAVrh10) into the lumbar cistern led to transgene expression in 60 to 90 % of the cells in the spinal cord. The transgene was expressed in all cell types, including neurons, glia, ependymal cells, and endothelial cells. Additionally, the transgene was expressed in some brain areas up to the frontal cortex and the olfactory bulb. The rAAV was distributed predominantly in the spinal cord, where its genome copy was over ten times that of the peripheral organs. Compared with intravenous injection, another method for rAAV delivery to the broad central nervous system (CNS), the intrathecal injection reduced the dosage of rAAV required to achieve similar or higher levels of transgene expression in the CNS by~100-fold. Finally, the transduced areas were co-localized with the perivascular spaces of Virchow-Robin, from which the rAAV spreads further into the CNS parenchyma, thus suggesting that rAAV penetrated the CNS parenchyma through this pathway. Taken together, we have defined a fast and efficient method to deliver widespread transgene expression in mature spinal cord in mice. This method can be applied to stably overexpress or silence gene expression in the spinal cord to investigate gene functions in mammalian CNS. Additionally, this method can be applied to validate therapeutic targets for spinal cord diseases.
Introduction
Efficient and sustained expression or suppression of the gene of interest in vivo is a powerful tool for investigating gene function in mammalian tissues including the central nervous system (CNS). Currently, this is mostly achieved through genome modification in mice (e.g., transgenic mice with random transgene insertion or targeted gene knockin or knockout). However, these processes are extremely time-consuming and expensive. For selective transgene expression in mature adult CNS, construction of transgenic mice with conditional transgene expression is necessary. This process requires construction of multiple transgenic lines and intercrossing them to obtain desired genotype [1] , thus further exacerbating the problem of long experiment time and high cost.
To circumvent this problem, recombinant viral vectors are often used to deliver transgene expression. Recombinant adeno-associated viruses (rAAVs) are increasingly becoming the vector system of choice for gene expression in vivo because of its broad cell and tissue tropism, efficient gene transfer, long-lasting transgene expression, minimal immunogenicity, and toxicity [2] . For application in the CNS, the vector is commonly stereotactically injected into the parenchyma or ventricles, leading to transgene expression in the vicinity of the injected areas. While this is well suited for investigating gene function in compact areas of the brain, such as the amygdala, nucleus accumbens, or substantia nigra, it is difficult to investigate gene function in the spinal cord due to its long linear structure.
Recent evidence has shown that intrathecal injection into the CSF in lumbar cistern may be advantageous in delivering transgene expression to the spinal cord. According to the classical model of CSF circulation, the CSF is secreted from the choroid plexus in the ventricles, flows through the ventricles, and exits into the cistern magnum through the median and lateral apertures of the fourth ventricle. It then circulates through the subarachnoid space around the spinal cord and upward to the arachnoid granulation, where it is absorbed into the superior sagittal sinus and returns into the blood stream. Based on this knowledge, the rAAVs injected into the lumbar cistern should follow CSF flow through the entire length of the spinal cord and possibly further to the forebrain. Numerous studies have tested this idea, and the widest distribution of gene transduction was achieved compared with other approaches [3] [4] [5] [6] [7] [8] [9] [10] . Several studies showed strong gene transduction along the entire length of the spinal cord following a single injection into the CSF [8] [9] [10] .
Despite these advances, further understanding and improvement of this approach are needed for its wide use in studies of gene function in spinal cord. For example, it is not yet clear whether there are advantages in using intrathecal injections over intravenous injections. The relative extent of CNS and peripheral transduction following intrathecal delivery of rAAV remains unknown. Current delivery methods in small animals such as mice include lumbar laminectomy and intrathecal catheterization, which are tedious, invasive, and injurious, resulting in highly variable and unpredictable transduction outcomes [8] . Furthermore, how the rAAV injected into the CSF spreads into the CNS parenchyma remains a mystery. To address these questions, we conducted a systematic study on the biodistribution of rAAVrh10 following a single intrathecal injection by lumbar puncture in mice. Although lumbar puncture in mice is technically more challenging than in larger animals, we chose this species because mice are most used to construct genetic models for human diseases. Therefore, technical optimizations in rAAV delivery can be directly applied in testing hypotheses on disease mechanism and therapy.
In this study, we injected the rAAV into the lumbar cistern and showed that a single injection consistently led to robust transduction of neurons, glia, ependymal cells, and endothelial cells along the entire length of the spinal cord and that transduction spread as far as the forebrain and olfactory bulb. We compared transduction patterns between mice that were injected intrathecally with those that were injected intravenously. We found that the intrathecal injections produced ten times higher rAAV biodistribution in spinal cord than in peripheral organs, whereas intravenous injections produced the opposite rAAV biodistribution pattern. Intrathecal injections yielded higher CNS rAAV biodistribution even with a dosẽ 100 times lower than intravenous injections. Moreover, we analyzed the spatial pattern of the rAAV gene transduction and found that the pattern was co-localized with the perivascular space of Virchow-Robin. These results suggest that rAAV injected into the CSF spread into the CNS parenchyma through this channel. Based on these findings, we conclude that intrathecal injection of rAAVrh10 is a simple and fast method to deliver broad transgene expression throughout the spinal cord. By incorporating overexpression or knockdown constructs, this rAAVrh10 delivery method can be a highly efficient tool for investigation of gene functions in the spinal cord.
Material and Methods rAAV Vector and Delivery
The gene cassette expressing EGFP and a scrambled artificial miRNA (amiR-Scr) is driven by cytomegalovirus enhancer/ chicken β-actin promoter. The amiR-Scr is placed in an intron located in the 3′ untranslated region (UTR). This selfcomplementary rAAV construct was built, produced, and used as described previously [8, 11] . FVB/NJ mice were purchased from the Jackson Laboratory and bred in the animal facility of the University of Massachusetts Medical School. The mice aged 30-70 days were used in the experiments. All mouse experiments were approved by IACUC and conducted according to UMMS policies and procedures regulating the use of animals in research and the provisions of the PHS/ NIH Guide for the Care and Use of Laboratory Animals.
Direct lumbar puncture [12] was used to deliver the rAAV vector. The injection was conducted in awake, conscious mice using the following procedure: A soft cloth was placed over the head and upper body of the animal to keep it calm. The animal was gripped firmly, but gently, by the pelvic girdle. The skin above the ileac crest was shaved and cleaned with alcohol. A 27-gauge needle connected to a 50-μl Hamilton syringe was inserted at the midline directly between the vertebrae at the level of the cauda equina. Once we observed the reflexive tail flick that is indicative of puncture of dura, 8 μl of PBS containing 4×10 10 rAAV and 1 % lidocaine hydrochloride (Sigma) was injected. After injection, the needle was maintained in place for~1 min before withdrawal and the animal was released in its cage. A transient weakness of the mouse limbs was monitored to assess the degree to which the injection reached the CSF: score 0 indicated no weakness, score 1 minor weakness of hind limbs without obvious gait abnormality, score 2 moderate weakness of hind limbs with gait abnormality, score 3 paralysis of hind limbs, score 4 paralysis of hind limbs and moderate weakness of fore limbs, and score 5 paralysis of all four limbs. The injected mice were maintained for 3 weeks and sacrificed for evaluation of transduction efficiency, which was then correlated with the original weakness score in the individual animals.
Histological Processing, Immunostaining, and Quantitative Analysis Mice were deeply anesthetized at 21 days post-injection and transcardially perfused with ice-chilled PBS followed by cold fixation buffer containing 4 % paraformaldehyde in PBS. The brain and spinal cord were dissected and post-fixed by soaking in the same fixative for 48 h. Tissues were cryoprotected in 30 % sucrose for 24-48 h and then embedded in OCT compound. Twenty micron frozen sections were cut using a Thermo cryostat.
For immunofluorescence staining, free-floating sections of the brain and spinal cord or whole mount of ventral, dorsal roots, and dorsal root ganglia (DRG) were incubated in 1 % Triton X-100 in PBS for 30 min, washed with PBS for 2 min, and then incubated in blocking solution containing 10 % serum, 0.05 % Triton X-100, and 0.05 % Tween 20 in PBS for 30 min at room temperature. Primary antibodies in the blocking solution were added to the sections or roots and incubated at 4°C overnight. The primary antibodies and dilutions used were as follows: rabbit anti-GFP (Invitrogen G10362, 1: 330) was used with mouse anti-NeuN (Millipore MAB377, 1:100), GFAP (Cell Signaling #3670S, 1:500) or APC (EMD Bioscience OP80-100UG, 1:400); mouse anti-GFP (Life Technologies, A11120, 1:330) was used with rabbit anti-Iba1 (BioCare Medical CP290A, B, 1:500), AQP4 (Alomone lab AQP-004, 1:200) or CD31 (Bioss bs-0468R, 1:300). Following the incubation, sections or roots were washed in PBS three times for 5 min each, incubated in the appropriate secondary antibody at room temperature for 90 min, washed three times for 5 min each, mounted with VECTASHIELD mounting solution and sealed with nail polish. Images of the brain, spinal cord sections, and roots were taken with a Leica TCS SP2 Confocal Microscope.
For immunohistochemistry, free-floating sections of the brain and spinal cord were pre-treated with 1 % H 2 O 2 for 10 min and then washed three times in PBS. After incubation with blocking solution containing 5 % normal serum and 0.3 % Triton X-100 in PBS, primary antibodies in the blocking solution were added to the sections and incubated at 4°C overnight. Following incubation, sections were washed three times in PBS containing 0.25 % Tween 20 (PBST) for 5 min each, and then incubated in appropriate biotin-secondary antibody at room temperature for 120 min. Sections were then washed three times in PBST, stained following the manufacturer's instructions for VECTASTAIN ABC kit and Elite PK-6100 standard ImmPact tm DAB peroxidase Substrate kit SK-4105 (Vector Lab). The sections were then mounted on slides and dried. After soaking in xylene two times for 2 min each, the slides were sealed with Permount (Vector Lab) and photographed with Olympus CX41 microscope equipped with an Evolution MP 5.0 RTV CCD (Color-Media Cybernetics, Canada).
Staining intensities in the digital images of transverse spinal cord sections were measured in grayscale using Image-pro plus 6.0 software. For analysis of EGFP-positive cells, photographs made with ×40 objectives were used to count the total number of GFP-positive cells manually. Briefly, three different lumbar and cervical sections from each well-injected mouse (scored at 4-5) were stained for EGFP, counterstained with hematoxylin, and analyzed. All cells with a clearly visible nucleus in one ×40 field (72-194 cells) per section were counted. Cells with dark brown staining were classified as GFP-positive, cells with light-brown staining as possible GFP-positive, and cells without brown staining as GFP-negative. The percentage of GFP-positive, probable GFP-positive, and negative cells in each region were recorded.
rAAV Genome Copy Number and RNA Quantification Tissues were quickly harvested, snap frozen in liquid nitrogen, and stored at −80°C. Total DNA or RNA from~10-20 mg of tissue blocks was extracted using the QiaCube HT instrument and reagent kits (Qiagen) according to the manufacturer's protocols. Total DNA was extracted using the QIAamp 96 DNA QIAcube HT kit (Qiagen, 51331), and digested with EcoRI (NEB) at >10 U/μg of DNA under 37°C for 1 h. There are two EcoRI sites in the rAAV genome. The EcoRI digestion ensures single copies of EGFP transgene for droplet digital PCR (ddPCR) quantification. Multiplexed ddPCR was performed on a QX200 ddPCR system (Bio-rad) using Taqman reagents targeting EGFP (Invitrogen, Assay ID Mr00660654_cn) and the reference gene transferrin receptor (Tfrc) (Invitrogen, 4458367). rAAV genome copy numbers per diploid genome were calculated as EGFP transgene copy numbers per two Tfrc gene copies. Total RNA was extracted using the RNeasy 96 QIAcube HT kit with onc o l u m n D N a s e I d i g e s t i o n ( Q i a g e n , 7 4 1 7 1 ) . Approximately 1.5 μg of total RNA was reverse transcribed into cDNA (Invitrogen 4368813) and subjected to multiplexed ddPCR using Taqman reagents targeting EGFP (Invitrogen, Assay ID Mr00660654_cn) and beta g l u c u r o n i d a s e ( G U S B ) ( I n v i t r o g e n , A s s a y I D Mm01197698_m1). The quantity of EGFP mRNA was normalized to GUSB mRNA and expressed as EGFP mRNA copy numbers per GUSB mRNA copy.
Western Blot
Total protein was extracted from frozen tissue by homogenization in a solution containing 1 % SDS, 25 mM phosphate (pH 7.6), 1 mM EGTA, and Halt Protease Inhibitor Cocktails (Thermo Scientific). The protein concentration was determined by BCA assay (Pierce) according to the manufacturer's protocol. To detect GFP protein, 30 μg of total protein was separated on a 15 % SDS-polyacrylamide gel (Bio-Rad) and wet transferred to a Protran ® (Whatman GmbH) nitrocellulose transfer membrane. The membrane was probed with rabbit anti-GFP antibody (Cell Signaling 2555S) and donkey antirabbit IgG (Amersham ECL NA34) secondary antibody. The protein bands were visualized using SuperSignal West Pico kit (Pierce).
Results rAAVrh10 Transduces Full Length of the Spinal Cord Following Injection into the Lumbar Cistern
To find an efficient method to deliver rAAVrh10 to the spinal cord, we tested the lumbar puncture method in mice. To gauge how rAAV spreads after injection, we first tested using Trypan blue. To monitor the quality of each injection, we added 1 % lidocaine hydrochloride to the injection solution. Well-injected animals where the injection went into the subarachnoid space were expected to show transient paralysis of the limbs whereas poorly injected animals would show no or mild weakness. As expected, mice showed various degrees of transient weakness or paralysis for 2-4 min and then resumed normal activity. We established a semi-quantitative 5-point scoring system for the various degrees of transient limb weakness (see "Material and Methods"). In well-injected animals that scored 4 or 5, the dye spread throughout the entire spinal cord and up to the furthest CNS areas such as the olfactory bulb within 10 min after injection (Fig. S1 ). Thus, the solutes injected into the CSF by lumbar puncture can spread rapidly throughout the CNS.
Next, we injected rAAVrh10-EGFP and tested whether we could use the 5-point scoring system for the various degrees of lidocaine-induced limb weakness immediately after injection to predict the extent of rAAV gene transduction that would be evaluated 3 weeks later. Of the ten mice injected, two showed no weakness (score 0), one showed minor weakness of hind limbs (score 1), four showed paralysis of hind limbs and moderate weakness of fore limbs (score 4), and three showed paralysis of four limbs (score 5) (Fig. S1 ). These mice were evaluated for their transduction levels by EGFP immunostaining of the spinal cord. The zero-scored mice manifested either no transduction or some transduction in the grey matter and in areas where nerve roots exit or enter the spinal cord (Fig. 1a) ; the one-scored mouse was similar to the zero-scored mice but had a slightly increased transduction (Fig. 1a) ; the four-and five-scored mice showed strong and global transduction in the whole spinal cord with the highest transduction in the nerve root entry or exit zones and patches of strong transduction in the white matter (Fig. 1a) . We quantified the GFP staining intensity, which showed a positive correlation with the extent of transient limb weakness in individual mice (Fig. 1b) . Therefore, we concluded that the severity of paralysis can be used to assess the quality of injection and predict the extent of transduction.
We further examined the spinal cord transduction in wellinjected mice and noticed that the full length of the spinal cord was well transduced (Fig. 2) . Particularly notable were the strong GFP-positive areas including the ventral and dorsal horns, the ventral effluent motor axons, and dorsal affluent sensory axons (Fig. 2, areas A, B, D, G, H, I , J, and L). In the spinal cord, motor neurons at all levels were robustly transduced (Fig. 2, areas A, G, and I) . Moreover, the grey matter areas strongly expressed GFP and white matter areas contained slightly less GFP-positive cells. However, a quantitative assessment of transduced cells showed a similarly high percentage of transduced cells in both areas (Fig. 3) , thus indicating that the relatively weaker staining in the white matter reflected a relatively lower cell density compared with the grey matter. Overall, between 60 and 90 % of the cells in the spinal cord were GFP-positive (Fig. 3) .
To confirm the cell types that were transduced, we carried out double immunofluorescence staining. We detected GFP expression in motor neurons and glial cells such as astrocytes, oligodendrocytes, and microglia (Fig. 4) . Additionally, we found robust GFP expression in DRG neurons as well as Schwann cells in the ventral and dorsal roots (Fig. S2) , thus indicating that intimate exposure to the CSF provides easy access to the rAAV.
rAAVrh10 Transduces Cells in Areas Near the Surface of Brainstem But Broadly in Cerebellum
To examine whether rAAVrh10 could spread beyond the spinal cord, we investigated transduction patterns in the brainstem and cerebellum from well-injected mice. Generally, the brainstem and cerebellum were widely transduced (Figs. S3-S6 ). In the lower medulla, transduction was detected in both deep and superficial areas with the latter showing stronger transduction (Fig. S3 ). In the rostral medulla ( Fig. S4 ) and pons (Fig. S5) , the superficial areas were strongly transduced and few cells were observed in the deep areas. Similarly, we observed strong and weak transduction in superficial and deep areas, respectively, in the midbrain (Fig. S6) . Thus, the pattern of transduction in brainstem indicates that the exposure and distance to the CSF determined efficiency of rAAVrh10 transduction.
Despite weak transduction in the deep regions of the rostral brainstem, many of the brainstem nuclei were robustly transduced, including the oculomotor nucleus (Fig. S6, area A) , trigeminal nucleus, facial nucleus ( (Fig. 5, area C, Fig. S6 , areas G, I, and J). Among the cells transduced in the brainstem nuclei, both neurons and glial cell were GFP-positive. In addition, robust GFP signals were detected in axon tracks, including inferior cerebellar peduncle (Fig. S3 , area G; Fig. S4 , area E), spinal trigeminal tract (Fig. S3, area G,  Fig. S4, area F; Fig. S5 , area E), and solitary tract (Fig. S4, area  A) , suggesting that neurons from which these fibers originate were transduced. Pyramidal tracts expressed EGFP but the signal was not as strong as the other tracks (Figs. S3-S5 ). Many glial cells were transduced in or near the pyramidal tract (Fig. S3,  area D; Fig. S4, area H; Fig. S5, area B) .
The cerebellum was widely and strongly transduced, including Purkinje cells, granule cells, cells and axons in the white matter, and deep cerebellar nuclei (Fig. S5) . hippocampus, and olfactory bulb ( Fig. 5; Figs. S7 and S8 ). Caudal coronal forebrain section containing the midbrain and hippocampus showed readily detectable transduction of parietal and temporal cortices. The transduced cells were distributed along the surface of the cortex in patches, which extend from the surface into deep layers of the cortex, reaching layer VI in many areas (Fig. 5, arrows in the center panel) . Within these cortical patches, most EGFP-positive cells were neurons with well-marked apical dendrites (Fig. 5, areas J, M, and N) . However, some scattered or clustered GFP-positive glial cells can also be detected (Fig. 5, areas M, N, and R) . In addition, the hippocampus was differentially transduced with EGFPpositive neurons scattered in the dentate gyrus (Fig. 5, area  K) . Numerous EGFP-expressing cross-sectioned fibers and interneurons were found in the polymorphic layer of dentate gyrus (Fig. 5, area O) . Furthermore, many EGFP-positive fibers were also observed in the inner third of the molecular layer of dentate gyrus (Fig. 5, area P) . CA3 of the hippocampus was highly transduced, including pyramidal, molecular, and oriens layers (Fig. 5, areas L and Q) . Neurons in CA1 of the hippocampus were lightly transduced, while fibers in oriens and radiatum layers were moderately transduced (not shown). In contrast, the midbrain covered by the forebrain (Fig. 5, areas A-H) was relatively less transduced compared with its caudal part that was exposed to the CSF (Fig. S6 ). Marginal areas including medial mammillary nucleus (Fig. 5, area A) , rostral interpeduncular nucleus (Fig. 5,   area B) , posterior intralamina thalamic nucleus (Fig. 5, area F) , medial genic nucleus (Fig. 5, area G) , and superior colliculus (Fig. 5, area I) were strongly transduced. Substantia nigra (Fig. 5 , area C) and parabrachial pigmented nucleus (Fig. 5 , area D) were moderately transduced, while only a few cells were transduced in the deep areas (Fig. 5, areas E and H) . Generally, GFP-positive cells in the deep areas away from the CSF were mostly astrocytes with abundant ramifications (Fig. 5, area E) .
Rostral coronal brain sections generally displayed a similar transduction pattern. The external cortex areas of each semisphere such as the cingulate cortex and indusium griseum near the median fissure were strongly transduced, while deep thalamus areas were poorly transduced (Fig. S7, areas A and  B) . Most of the cortex was highly transduced, with noticeably higher EGFP-positive neurons and glial cells observed among all the cortical layers (Fig. S7) . Deep areas showed low transduction with a few clusters of glial cells and evenly distributed fibers in the corpus callosum (Fig. S7, area D) . Sparse EGFPpositive neurons and glial cells were observed in the caudate putamen (Fig. S7, area G) ; however, midline areas that included dorsal peduncular cortex (Fig. S7 , area E) and medial septal nucleus (Fig. S7 , area H) were transduced. Meanwhile, fibers and a few glial cells were transduced in the anterior commissure (Fig. S7, area J) . A number of glial cells were EGFP-positive in the core nucleus accumbens (Fig. S7, area K) . Moreover, ventral pallidum (Fig. S7, area I ) and nucleus of vert limb diagonal band (Fig. S7, area L) were prominently transduced. The most rostral part of the mouse brain where the olfactory bulb is located also showed a clustered transduction pattern (Fig. S8 ) of EGFPpositive neurons (Fig. S8, areas A, B , and D) and glial cells (Fig. S8, area C) in the periphery and center of the olfactory bulb.
Similar to the spinal cord (Fig. 4) , double immunofluorescence staining confirmed that all the major CNS cell types, including neurons, astrocytes, oligodendrocytes, and microglia were transduced in the brain (Fig. S9) .
Injection of rAAVrh10 by Lumbar Puncture Causes No Detectable Neuroinflammation
CNS neuronal damage caused by immune responses to viral gene transfer had been reported in rAAV-mediated transductions [13, 14] . Likewise, we also observed astrogliosis and microgliosis after intrathecal delivery of rAAVrh10 through a catheter implanted by laminectomy [8] (data not shown), suggesting a presence of injury using that approach. To determine whether rAAVrh10 delivery by lumbar puncture caused similar injury, we examined gliosis in the robustly transduced areas such as the lumbar and cervical regions of the spinal cord as well as the cerebral cortex. No astrogliosis, microgliosis, or neuronal loss was detected (Fig. S10) , suggesting that intrathecal injection of rAAVrh10 into the CSF by The spread of the CSF-injected rAAV and its transduction of cells deep in the CNS parenchyma raised the question as to how viral particles penetrate into the CNS tissue. In the spinal cord and brain sections, we noticed that rAAV transduction was often distributed along imaginative lines penetrating the deep CNS parenchyma from the surface (Fig. 6 , arrows in the panels in the center of Figs. 2 and 5; Figs. S4 and S5 ). This pattern was similar to that observed when macromolecular tracers were injected into the CSF, demonstrating that these tracers reached the CNS parenchyma through the perivascular spaces of Virchow-Robin [15, 16] . Therefore, we postulated that rAAV particles injected into the CSF penetrate and spread 5 rAAVrh10 injected into the lumbar cistern transduced regions in the cortex, hippocampus and rostral midbrain: a medial mammillary nucleus, b rostral interpeduncular nucleus, c substantia nigra, d parabrachial pigmented nucleus, e red nucleus, f posterior intralaminar thalamic nucleus, g medial geniculate nucleus, h periaqueductal grey, i superior colliculus, k, o, p dentate gyrus, l, q CA3 of the hippocampus, j, m, n, r cortex. Note that the temporal cortex had higher level of transduction compared with the parietal cortex; in the hippocampus, the most prominent level of transduction was found in dentate gyrus and CA3; in the midbrain, most transduction was in the peripheral regions. Arrows in the central panel point to patches of transduction that appeared to project from the edge into the parenchyma of the brain (see text). Bar=50 μm EGFP-stained patches was co-localized with the AQP4-positive perivascular channels in the cortex. From these channels, the EGFP signal spread laterally (Fig. 7a) . Furthermore, a similar co-localization pattern was observed in the spinal cord (Fig. 7a) . Lastly, we also observed strong transduction in endothelial cells (Fig. 7b) . These results suggest that rAAVs gain access to the CNS parenchyma through the perivascular channels.
Intrathecal Injection of rAAVrh10 by Lumbar Puncture Enhances the CNS Gene Transduction
Although intrathecal injections of rAAV have been used in several previous studies, a systematic study on the transduction levels in various regions of the CNS relative to the periphery had not been conducted. To fill this gap, we measured rAAV genome copies for the rAAV distribution and measured EGFP mRNA and protein levels for the transgene expression in well-injected animals with weakness scores of four and five (Fig. 1) . The results revealed four patterns (Fig. 8) . First, with an exception to the cerebellum, genome copies of rAAV were generally higher in the CNS than in the periphery (Fig. 8a,  black bars) . Notably, our results show that of all the CNS regions, the lumbar spinal cord showed ten times more genome copies than the most transduced peripheral organ, the adrenal gland (Fig. 8a, black bars) . Second, within the CNS, regions near the injection site generally had higher rAAV genome copies than the more distal regions (Fig. 8a , black bars) with the exception of the cerebellum, which showed exceedingly low biodistribution (Fig. 8a, black bars) . Third, the levels of EGFP expression showed a gradient that ranged from high near the injection site to low at more distant sites. Fourth, when comparing the highest EGFP levels from both CNS and peripheral tissues, we observed more EGFP expression in the adrenal gland and heart than the lumbar spinal cord (Fig. 8b, c) . Other peripheral organs such as the liver and skeletal muscle also expressed EGFP levels higher than most CNS regions. Taken together, the transgene expression did not follow the pattern of rAAV distribution. Indeed, when normalized against the genome copy, several peripheral tissues (heart, adrenal gland, muscle, and liver) showed higher transgene expression efficiency (TGEE) than the CNS tissues with the exception of the cerebellum, which showed a level of TGEE comparable to the highest peripheral tissue (Fig. 8d) .
The relative transduction levels in the CNS and the periphery might be determined by the injection quality. For example, in our previous study where the animals were injected by laminectomy and intrathecal catheterization method, only the well-injected animals showed relatively higher CNS transduction than the periphery. On the other hand, poorly injected animals showed relatively higher peripheral transduction than the CNS because most of the rAAV may have leaked to the periphery during injection [8] . To examine this in animals injected by lumbar puncture method, we investigated the Fig. 6 The rAAV transduction was distributed as long patches projecting from the surface into the parenchyma of the spinal cord and the cortex: a lateral and b anterior funiculi of the CSC, c lateral funiculus of the LSC, d frontal cortex, e parietal cortex, f temporal cortex, g, h ventral medial part of pons, i ventral anterior part of pons, j ventral lateral part of pons. Bar=100 μm rAAV biodistribution and EGFP expression in poorly injected animals with low weakness score (Fig. 1) . Our results showed that poorly injected animals had lower transduction levels in both the CNS and peripheral tissues than well-injected animals ( Fig. 8a, b ; comparing white bars with the black ones), but the relative ranking of transduction in various CNS regions and peripheral organs remained largely the same between the well-injected and poorly injected animals ( Fig. 8a, b ; comparing the white bars or the blank bars among themselves). At the protein level, the intensity of EGFP expression is also correlated with the injection quality score in both the CNS and the periphery. Animals with a high injection quality score showed stronger transduction in both the CNS (Fig. 1) and the periphery than those with a low injection score ( Fig. 1; Fig. S11 ).
The broad CNS transduction can also be achieved by intravenous administration of rAAV in adult animals [17, 18, 11, 19] . However, the transduction efficiency has not been quantitatively compared side-by-side with the intrathecal delivery. To obtain this data, we compared the genome copies of rAAVrh10 in different organs between the levels achieved by the intrathecal injection and those achieved by intravenous injection that we reported previously [19] . The intrathecal injection delivered rAAV predominantly to the CNS (spinal cord and brain), whereas the intravenous injection delivered rAAV predominantly to the periphery (e.g., liver and muscle) (Fig. 8e) . Notably, the intrathecal injection achieved higher levels of CNS transduction than the intravenous injection with doses that were two orders of magnitude lower (~10 12 vs. 10 14 vg/kg).
Discussion
In this study, we characterized transduction patterns of rAAVrh10 in the CNS following its intrathecal injection into the lumbar cistern. We show that this method can deliver widespread and robust transgene expression throughout the entire spinal cord (Fig. 2) . Sixty to 90 % of cells in the spinal cord, including neurons (motor neurons, sensory neurons, and interneurons) and glia (astrocytes, oligodendrocytes, and microglia) showed transgene expression ( Figs. 3 and 4 ; Fig. S2 ).
In addition, gene transduction had spread to many brain regions including the olfactory bulb, the most anterior region of the mouse brain ( Fig. 5 ; Figs S3-S8). Similar to the spinal cord, rAAVrh10 transduced all major CNS cell types in the brain (Fig. S9) . These results achieved unprecedented viral vector-mediated gene transduction in the spinal cord, thus providing a means to investigating gene functions in this region.
The rAAV distribution in the CNS following CSF injection in the lumbar cistern is largely consistent with CSF flow pattern, suggesting that dispersion of rAAV in the CNS is at least in part assisted by the CSF flow. However, this did not hold true for all cases as we observed higher viral genome copies in the olfactory bulb than the cortex, and higher in the hippocampus and cortex than in the cerebellum (Fig. 8a) . In both cases, the latter regions encounter the rAAV brought by the CSF flow ahead of the former regions. Deviations from the CSF flow suggest that other factors also contribute to rAAV biodistribution. One such factor may be the ratio of surface area to volume of a region. Therefore, a higher ratio or larger surface area exposes the region to more CSF containing the rAAVs. This could explain the higher viral genome copies in the olfactory bulb and hippocampus than in the cortex and the cerebellum, respectively. Another contributing factor could be regional differences in the rAAV tropism. For example the rAAVrh10 may have lower tropism for cells within the cerebellum than other parts of the brain, resulting in the lowest rAAV biodistribution within the cerebellar region among all CNS areas. Overall, our results suggest that the exposure and Despite the increasing literature on the delivery of rAAV to the CNS by injection into the CSF, how the rAAV penetrate into the CNS parenchyma was not known. We found that the most intensely transduced areas in the spinal cord and brain were co-localized with the perivascular space of VirchowRobin and a transduction gradient that spreads from this channel to the neighboring CNS parenchyma (Figs. 6 and 7a) . These results suggest that rAAV delivered into the CSF gain access to the CNS parenchyma through this pathway. Previous reports have shown that macromolecular tracers penetrate into the brain parenchyma through the same channels, which support this scenario [16, 20] . If this pattern is confirmed in further studies in different mammalian species, the abundance and depth of the penetrating perivascular spaces may predict the degree of transduction in the CNS parenchyma following rAAV delivery via CSF.
Although the perivascular space is likely the predominant channel through which the rAAV spreads into the CNS parenchyma, other routes are likely to also contribute. For example, transduction was also strongly co-localized with the ventral root exit and dorsal root entry zones (Figs. 1 and 2 ). Strong transduction in glial cells surrounding the ventral and dorsal root axons (Fig. 2, areas B , D, J and L; Fig. 3a) suggests that [19] and those injected intrathecally (IT). LSC lumbar spinal cord, TSC thoracic spinal cord, CSC cervical spinal cord, BS brainstem, Ce cerebellum, Hi hippocampus, CTX cortex, OB olfactory bulb, Ht heart, Li liver, Sp spleen, Lg lung, Ki kidney, AG adrenal gland, SM skeletal muscle, Br brain. All error bars are standard deviation axon tracks also facilitate the rAAV distribution into the CNS parenchyma. In addition, GFP-positive cells (mostly astrocytes and some isolated neurons) were also observed in areas that are deep and furthest from the CSF and apparently not associated with the penetrating perivascular spaces (e.g., Fig. 5e , h; Suppl. Fig. 3B, C ; the center panel of Suppl .  Figs. 4 , 5, and 6; Suppl. Fig. 7E, F, G, H, J, K) . It is not clear how the rAAV reach these deep areas. However, a small fraction of rAAV might spread trans-synaptically via long projecting axons and/or enter the blood stream and recirculate to reach the deep CNS parenchyma.
Comparisons between rAAV distributions following intrathecal injection and intravenous injection demonstrate that intrathecal injection is more efficient in delivering rAAV into the CNS, particularly the spinal cord (Fig. 8e) . Other studies have also concluded that CSF injection is more efficient in delivering rAAV into the CNS [9, 10] . However, peripheral distribution of the rAAV was also readily detectable following intrathecal injection, albeit at lower levels (particularly in liver) than in the CNS (Fig. 8a) . Similar peripheral distribution has also been detected in other studies where rAAV9 or rAAVrh10 was injected into the CSF [9, 10] . In this study, we analyzed both well-injected and poorly injected animals and found that the rAAV distribution in both the CNS and the periphery changed in concert with quality of injection. Well-injected animals showed higher levels of rAAV distribution than poorly injected animals in both the CNS and periphery (Fig. 8a) . This finding suggests that the peripheral distribution was not a result from leakage of viral particles during the injection, but rather, systematic factors caused rAAVs to be consistently distributed to the periphery. It has been reported previously that small and macro molecules injected into the CSF can lead to blood distribution rapidly [21] [22] [23] . It is possible that structural conduits, such as the CSF drainage to the lymphatics, permitted the rAAV in the CSF to flow into the blood circulation [24] . Alternatively, the rAAV might cross arachnoid villi into the blood stream [25] . The exact channel through which the rAAV is distributed to the periphery remains to be determined by further investigation.
Our measurements of rAAV genome copies and the expression levels in different regions of the CNS and peripheral tissues have provided the first glimpse into the relationship between the rAAV distribution and the levels of transgene expression following the intrathecal delivery. In the CNS, both genome copies and mRNA levels displayed a gradient from the highest near the injection site to the lowest at the distant sites (Fig. 8a, b) . When the data was presented as the mRNA level per rAAV genome or transgene expression efficiency (TGEE), an opposite gradient emerged: the TGEE was positively correlated with the distance from the injection site (with the cerebellum being the exception) (Fig. 8d) . For example, the olfactory bulb is the farthest CNS region from the injection site, yet it expressed EGFP mRNA per rAAV genome~4 times higher than the lumbar spinal cord, the region that was the closest to the injection site (Fig. 8d) . The variation in the levels of the GUSB mRNA, which was used to normalize the EGFP mRNA level, ranged from the lowest in the lumbar spinal cord to the highest (by~65 %) in the olfactory bulb, and therefore, is not the cause for the correlation between the expression efficiency and the distance from the injection site.
When we include the cerebellum and the peripheral tissues in the comparison, the phenomenon that the levels of rAAV distribution do not directly translate into the levels of transgene expression becomes more striking. For example, while the highest copies of rAAV genome were detected in the spinal cord (Fig. 8a) , the highest levels of EGFP mRNAs were found in the peripheral organs such as the adrenal gland and the heart (Fig. 8b, c) . By measuring both the genome copy numbers and the transgene expression levels, we were able to determine the TGEE. For each rAAV vector, the TGEE may not be predicted because it can be influenced by multiple factors, including the types of viral capsid, the vector promoter, the method of delivery, and the variables in the host tissues such as viral receptor, internalization, intracellular trafficking, uncoating, and genome processing [26] . Additionally, differences in tissue-and cell-specific regulation of gene expression could also affect the activity of the vector promoter, the levels of translation, and the stability of the transgene products (mRNA and protein). Given these considerations, selective spinal cord expression may be further enhanced by utilizing different serotype or CNS-specific vector promoters [27, 28] .
Conclusions
Administration of rAAV into the lumbar cistern is a highly efficient method to deliver widespread and robust transduction of rAAV in the spinal cord. Compared with intravenous injection, the intrathecal injection delivered more selective CNS transduction relative to the peripheral transduction. Additionally, the intrathecal injection delivered widespread rAAV transduction through the perivascular spaces in the CNS. In conclusion, this approach can be implemented to deliver transgene expression, to study gene function and to conduct pre-clinical therapeutic target validation in the spinal cord.
